MBC BioLabs

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Kit is a company focused on providing at-home medical exams and health testing services. It develops comprehensive health testing kits that enable insurers and telehealth companies to offer convenient and safe testing options for their patients from the comfort of their homes. These kits serve as a reliable alternative to traditional doctor and laboratory visits, making preventative health testing accessible across various industries. As a subsidiary of Ro, Kit is committed to enhancing the healthcare experience through innovative solutions.

Keyhole Therapeutics is a discovery stage drug company specializing in immunotherapies for cancer and autoimmune diseases. Keyhole's first program, a small molecule inhibitor of exosome release being investigated for promotion of immune-driven tumor destruction in cancer patients resistant to current immune checkpoint inhibitors, is at the hit-to-lead stage. Future programs will include additional inhibitors of exosome release, and novel exosome-related therapeutic opportunities for cellular cancer vaccines and for targeted suppression of autoreactive T cells. Keyhole Therapeutics is seeking bold, accomplished, and innovative scientists to join them in pioneering the next wave of immunotherapeutics.

Jupiter Therapeutics is a biotechnology company specializing in the development of cell-membrane-based therapeutics. The company employs a synthetic biology approach to rapidly design and synthesize a diverse pipeline of therapeutic assets targeting cancer, autoimmune diseases, drug delivery, and gene therapy. By utilizing advanced cell engineering techniques, Jupiter Therapeutics creates customized vesicles that enhance immuno-oncology applications and gene therapy strategies. This innovative approach allows medical researchers to leverage insights gained from cell-membrane studies to improve treatments involving CAR T-cells and bi-specific antibodies.

Factorial Diagnostics is focused on leveraging its novel NGS library prep methods and bioinformatics algorithms to commercialize high resolution, multi-omic, cancer diagnostic assays.

Single Helix Genomics specializes in the development of automated, portable devices for the on-demand manufacturing of therapeutics-grade mRNA. The company focuses on providing custom and pre-designed RNA products that comply with current Good Manufacturing Practice (cGMP) standards. Utilizing proprietary, single-use microfluidic biochips, Single Helix Genomics enables the consistent production of mRNA therapeutics and vaccines within hours. Their innovative system employs patent-protected hardware, software, and enzyme-based formulations, allowing for the rapid delivery of personalized mRNA therapies and vaccines to patients in less than two days. This approach aims to enhance the accessibility and efficiency of mRNA-based treatments in the field of drug discovery and healthcare.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.